Patent SG-11201903261V-A (SG)
Title: Oral composite tablet comprising ezetimibe and rosuvastatin
Inventor: SONG HAN BYUL
IPC: A61K9/20
Filed: 2017-11-24
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111010111 01111101011101011111011111111111110111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/101681 Al 07 June 2018 (07.06.2018) W I P0 I P C T (51) International Patent Classification: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, A61K 9/20 (2006.01) A61K 31/505 (2006.01) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, A61K 31/397 (2006.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (21) International Application Number: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, PCT/KR2017/013508 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (22) International Filing Date: 24 November 2017 (24.11.2017) Published: — (25) Filing Language: English with international search report (Art. 21(3)) (26) Publication Language: English (30) Priority Data: 10-2016-0160513 29 November 2016 (29.11.2016) KR (71) Applicant: HANMI PHARM. CO ., LTD. [KR/KR]; 214, Muha-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do 18536 (KR). _ (72) Inventors: SONG, Han Byul; 101-1204, 95, Deogyeong-daero 407beon-gil, Jangan-gu, Suwon-si, Gyeonggi-do 16356 (KR). CHO, Jung Hyun; 119-1004, _ 382-37, Dongtanwoncheon-ro, Hwaseong-si, Gyeonggi-do 18396 (KR). KIM, Jin Cheul; 506-401, 16, Dangsan-ro 42- gil, Yeongdeungpo-gu, Seoul 07216 (KR). KIM, Youg Il; = 732-504, 52, Jeongja-ro 42beon-gil, Jangan-gu, Suwon-si, = _ Gyeonggi-do 16325 (KR). PARK, Jae Hyun; 311-404, = 460, Yeongtong-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 16707 (KR). WOO, Jong Soo; 120-2303, 85, Hwasan-ro, Jangan-gu, Suwon-si, Gyeonggi-do 16420 (KR). = Agent: Y.P.LEE, MOCK & PARTNERS; 12F Daelim (74) _ Acrotel, 13 Eonju-ro 30-gil, Gangnam-gu, Seoul 06292 — (KR). = Designated States (unless otherwise indicated, for every (81) kind of national protection available): AE, AG, AL, AM, = = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, _ CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, = = MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, = — PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, — TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = Designated States (unless otherwise indicated, for every (84) kind of regional protection available): ARIPO (BW, GH, = 1-1 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Il QC (54) Title: ORAL COMPOSITE TABLET COMPRISING EZETIMIBE AND ROSUVASTATIN SO 1-1 (57) : An oral composite tablet and a method of preparing the same are provided. The oral composite tablet includes: an 1-1 © ezetimibe wet granule portion including ezetimibe; and a rosuvastatin mixture portion including rosuvastatin or a pharmaceutically ---- acceptable salt thereof, wherein the ezetimibe wet granule portion includes, as a binder, povidone having a weight average molecular GC weight of about 30,000 to about 50,000, and the rosuvastatin mixture portion includes a diluents including a water-soluble diluent and 1-1 © a water-insoluble diluent, the water-insoluble diluent having a particle size (d90) of about 98 i.tm to about 229 i.tm corresponding to f'1 90% in a cumulative particles size distribution of total particles. C